Ibrutinib for steroid refractory chronic graft-versus-host disease: therapeutic efficiency can be limited by increased risk of fungal infection

Panayotis Kaloyannidis; Ahmed Ayyad; Zakaria Bahaliwah; Belal Blowi; Wael Alanazi; Zahra Al Shammasi; Hamdi Elsoudi; Ibrahim Ibrahim; Hani Al Hashmi

doi:10.1038/s41409-021-01318-6

$Ibrutinib for steroid refractory chronic graft-versus-host disease: therapeutic efficiency can be limited by increased risk of fungal infection$

Journal article

Peer reviewed

Ibrutinib for steroid refractory chronic graft-versus-host disease: therapeutic efficiency can be limited by increased risk of fungal infection

Panayotis Kaloyannidis, Ahmed Ayyad, Zakaria Bahaliwah, Belal Blowi, Wael Alanazi, Zahra Al Shammasi, Hamdi Elsoudi, Ibrahim Ibrahim and Hani Al Hashmi

Bone marrow transplantation (Basingstoke), Vol.56(8), pp.2034-2037

01/08/2021

DOI: https://doi.org/10.1038/s41409-021-01318-6

PMID: 33947981

Abstract

Biophysics

Hematology

Immunology

Life Sciences & Biomedicine

Oncology

Science & Technology

Transplantation

Metrics

1 Record Views

See more details

Details

Title: Ibrutinib for steroid refractory chronic graft-versus-host disease: therapeutic efficiency can be limited by increased risk of fungal infection
Creators - without role: Panayotis Kaloyannidis - King Fahad Specialist Hospital
Ahmed Ayyad - King Fahad Specialist Hospital
Zakaria Bahaliwah - King Fahad Specialist Hospital
Belal Blowi - King Fahad Specialist Hospital
Wael Alanazi - King Fahad Specialist Hospital
Zahra Al Shammasi - STEM
Hamdi Elsoudi - King Fahad Specialist Hospital
Ibrahim Ibrahim - King Fahad Specialist Hospital
Hani Al Hashmi - King Fahad Specialist Hospital
Publication Details: Bone marrow transplantation (Basingstoke), Vol.56(8), pp.2034-2037
Publisher: Springer Nature
Number of pages: 4
Identifiers: 9949916408331
Academic Unit: King Saud University
Language: English
Resource Type: Journal article